Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Docosahexaenoic acid (DHA) and vitamin D3 is a nutritional supplement combination that has been studied for various health benefits. This combination has shown promising results in clinical trials, particularly for non-alcoholic fatty liver disease (NAFLD) in obese children with vitamin D deficiency. DHA is an omega-3 fatty acid found in cold-water fish like tuna and salmon. It plays a crucial role in the development of eye and nerve tissues and may reduce the risk of cardiovascular disease by decreasing blood thickness, reducing inflammation, and lowering triglyceride levels[3]. Vitamin D3 (cholecalciferol) is a fat-soluble vitamin that promotes calcium absorption, supporting bone health and immune function[5]. When combined, these nutrients have shown synergistic effects. In a randomized, double-blind placebo-controlled trial, DHA (500 mg) plus vitamin D (800 IU) treatment in obese children with biopsy-proven NAFLD and vitamin D deficiency resulted in: - Reduced NAFLD Activity Score (NAS) - Improved insulin resistance - Better lipid profiles - Decreased ALT levels - Reduced activation of hepatic stellate cells and fibrillar collagen content[1] The combination has been studied in several clinical trials: 1. A study of obese children with biopsy-proven NAFLD showed significant improvements in liver histology and metabolic parameters after 12 months of treatment with 500 mg DHA plus 800 IU vitamin D daily[1]. 2. Another multicenter, randomized, double-blind controlled study investigated the effect of vitamin D and DHA co-supplementation for six months on vitamin D status, body composition, and metabolic markers in obese children with vitamin D deficiency. While both groups showed improvement in vitamin D status, the DHA plus vitamin D group had higher increases in DHA levels, which could be relevant for preventing inflammatory complications of obesity[2]. 3. Recent research has also explored the combination with probiotics, showing benefits against aluminum-induced cognitive impairment[4]. This combination is primarily used as a nutritional supplement to: - Support cardiovascular health - Promote cognitive development and function - Enhance bone health - Strengthen the immune system - Manage nutritional deficiencies[5] It's often found in combination with other nutrients like methylfolate, methylcobalamin, and pyridoxal-5-phosphate in various formulations[5][6]. Potential side effects may include: - Gastrointestinal discomfort - Allergic reactions - Skin sensitivity - Mild nausea - Dizziness[5] DHA may interact with certain medications: - Antihypertensive drugs (may cause blood pressure to go too low) - Anticoagulants/antiplatelet drugs (may increase risk of bruising and bleeding) - Antidiabetic medications (may affect blood sugar levels)[3][5] This nutritional supplement combination represents a promising approach for addressing various health conditions, particularly those related to inflammation, metabolic disorders, and nutritional deficiencies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docosahexaenoic acid + vitamin D3.